Vir Biotechnology (NASDAQ:VIR) Now Covered by Analysts at SVB Leerink

SVB Leerink began coverage on shares of Vir Biotechnology (NASDAQ:VIRGet Rating) in a research note released on Wednesday morning, Marketbeat reports. The firm issued an outperform rating and a $40.00 target price on the stock.

Other equities analysts also recently issued research reports about the company. Morgan Stanley started coverage on Vir Biotechnology in a research report on Friday, September 9th. They set an underweight rating and a $15.00 price target on the stock. Barclays decreased their target price on Vir Biotechnology to $67.00 in a report on Monday, August 15th. Finally, HC Wainwright reaffirmed a buy rating and set a $125.00 price target on shares of Vir Biotechnology in a report on Thursday, July 14th. One analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, Vir Biotechnology presently has an average rating of Hold and a consensus price target of $52.38.

Vir Biotechnology Trading Up 2.2 %

NASDAQ VIR opened at $21.02 on Wednesday. Vir Biotechnology has a 12 month low of $18.21 and a 12 month high of $58.00. The stock has a 50 day moving average of $26.80 and a 200-day moving average of $24.79. The company has a market cap of $2.79 billion, a PE ratio of 2.62 and a beta of -0.29.

Vir Biotechnology (NASDAQ:VIRGet Rating) last announced its quarterly earnings results on Tuesday, August 9th. The company reported ($0.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.41). The firm had revenue of $40.60 million during the quarter, compared to analyst estimates of $211.14 million. Vir Biotechnology had a net margin of 52.29% and a return on equity of 68.86%. The business’s revenue was down 77.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.46 EPS. As a group, sell-side analysts predict that Vir Biotechnology will post 3.14 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, major shareholder Endurance (Cayman) Ltd Svf sold 122,564 shares of the company’s stock in a transaction dated Monday, August 15th. The shares were sold at an average price of $27.99, for a total value of $3,430,566.36. Following the transaction, the insider now directly owns 22,094,080 shares in the company, valued at $618,413,299.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, major shareholder Endurance (Cayman) Ltd Svf sold 122,564 shares of the business’s stock in a transaction that occurred on Monday, August 15th. The stock was sold at an average price of $27.99, for a total value of $3,430,566.36. Following the completion of the sale, the insider now directly owns 22,094,080 shares in the company, valued at $618,413,299.20. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Vicki L. Sato sold 17,915 shares of the firm’s stock in a transaction on Friday, July 8th. The stock was sold at an average price of $29.06, for a total value of $520,609.90. Following the transaction, the director now owns 1,470,664 shares in the company, valued at approximately $42,737,495.84. The disclosure for this sale can be found here. Insiders have sold 173,385 shares of company stock worth $4,767,741 in the last 90 days. Company insiders own 22.40% of the company’s stock.

Institutional Investors Weigh In On Vir Biotechnology

Institutional investors and hedge funds have recently bought and sold shares of the company. Nisa Investment Advisors LLC raised its position in shares of Vir Biotechnology by 127.3% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,000 shares of the company’s stock valued at $25,000 after buying an additional 560 shares in the last quarter. US Bancorp DE increased its stake in Vir Biotechnology by 175.1% in the second quarter. US Bancorp DE now owns 982 shares of the company’s stock valued at $25,000 after acquiring an additional 625 shares during the last quarter. SeaCrest Wealth Management LLC acquired a new position in Vir Biotechnology during the second quarter valued at approximately $36,000. Captrust Financial Advisors lifted its stake in Vir Biotechnology by 1,270.7% during the second quarter. Captrust Financial Advisors now owns 1,823 shares of the company’s stock worth $46,000 after purchasing an additional 1,690 shares during the last quarter. Finally, Banque Cantonale Vaudoise acquired a new position in shares of Vir Biotechnology during the 2nd quarter worth $63,000. Institutional investors own 64.55% of the company’s stock.

About Vir Biotechnology

(Get Rating)

Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus.

Featured Articles

Analyst Recommendations for Vir Biotechnology (NASDAQ:VIR)

Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.